Skip to content

Comparison of the efficacy and safety of radiofrequency ablation and robot-assisted partial nephrectomy for T1a renal tumors : a prospective randomized controlled study

Comparison of the efficacy and safety of radiofrequency ablation and robot-assisted partial nephrectomy for T1a renal tumors : a prospective randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500111493
Enrollment
Unknown
Registered
2025-10-31
Start date
2025-10-31
Completion date
Unknown
Last updated
2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cancer

Interventions

Radiofrequency ablation group:Radiofrequency ablation was performed on patients
Robotic partial nephrectomy group:Robot-assisted partial nephrectomy was performed on the patient

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Patients clinically diagnosed with stage T1a renal cell carcinoma, regardless of gender; 2.18 Age <=80 years old; 3. The RENAL score is low complexity (4-6 points); 4. Be capable of conducting regular follow-ups; 5. The patient and their family members expressed their knowledge of this study and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Refuse to undergo radiofrequency ablation treatment or robotic partial nephrectomy, or plan to undergo radical nephrectomy or other surgical treatment methods; 2. Patients who refuse to have their data collected; 3. Patients with other concurrent tumors; 4. Patients with severe decompensated underlying heart and lung diseases, severe bleeding tendency diseases and other surgical contraindications; 5. Pregnant or lactating women; 6. The patient and his/her family refused to participate in this study. 7. Situations that the researcher deems necessary to exclude.

Design outcomes

Primary

MeasureTime frame
Tumor recurrence rate;

Secondary

MeasureTime frame
Quality of life score;Resume daily activity time;Postoperative hospital stay;Operation time;Intraoperative and postoperative adverse events (contrast agent allergy, bleeding, infection, etc.);

Countries

China

Contacts

Public ContactXuesong Li

Peking University First Hospital

pineneedle@sina.com+86 158 0139 9116

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026